Efeitos do canabidiol no tratamento de pacientes com doença de Parkinson.

Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind tria

All authors: Marcos Hortes N Chagas, Antonio W Zuardi, Vitor Tumas, Márcio Alexandre Pena-Pereira, Emmanuelle T Sobreira, Mateus M Bergamaschi, Antonio Carlos dos Santos, Antonio Lucio Teixeira, Jaime EC Hallak, José Alexandre S Crippa

Introduction:

Parkinson’s disease (PD) has a progressive course and is characterized by the degeneration of dopaminergic neurons. Although no neuroprotective treatments for PD have been found to date, the endocannabinoid system has emerged as a promising target.

Methods:

From a sample of 119 patients consecutively evaluated in a specialized movement disorders outpatient clinic, we selected 21 PD patients without dementia or comorbid psychiatric conditions. Participants were assigned to three groups of seven subjects each who were treated with placebo, cannabidiol (CBD) 75 mg/day or CBD 300 mg/day. One week before the trial and in the last week of treatment participants were assessed

Results:

We found no statistically significant differences in UPDRS scores, plasma BDNF levels or H1-MRS measures. However, the groups treated with placebo and CBD 300 mg/day had significantly different mean total scores in the PDQ-39 (p = 0.05).

Conclusions:

Our findings point to a possible effect of CBD in improving

You can find the full version here.

This information is presented for educational purposes only. 1Pure. provides this information to provide an understanding of the potential applications of cannabidiol. Links to third party websites do not constitute an endorsement of these organizations by 1Pure and none should be inferred.

Esta informação é apresentada apenas para fins educacionais. 1Pure fornece informações para dar uma compreensão das aplicações potenciais do canabidiol. Links para sites de terceiros não constituem um endosso dessas organizações por parte da 1Pure e nada deve ser inferido.